Literature DB >> 338392

Pain relief in the post-operative period: a comparative trial of morphine and a new analgesic buprenorphine.

B C Hovell, A E Ward.   

Abstract

In a comparative trial, buprenorphine 0-3 mg or morphine 10 mg was administered intramuscularly to patients post-operatively. The new drug buprenorphine produced more pain relief than morphine and appeared to have a longer duration of action. The side-effects produced by the two drugs were similar, as were the effect on respiratory and cardiovascular measurements.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 338392     DOI： 10.1177/030006057300100206

Source DB:  PubMed          Journal:  J Int Med Res        ISSN： 0300-0605            Impact factor:   1.671


  6 in total

1.  Analysis of inflammation-induced depression of home cage wheel running in rats reveals the difference between opioid antinociception and restoration of function.

Authors:  Ram Kandasamy; Jonas J Calsbeek; Michael M Morgan
Journal:  Behav Brain Res       Date:  2016-10-13       Impact factor: 3.332

Review 2.  Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-02       Impact factor: 9.546

3.  A comparative study of intramuscular buprenorphine and morphine in the treatment of chronic pain of malignant origin.

Authors:  M Kjaer; H Henriksen; J Knudsen
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

4.  Effects of buprenorphine on motor activity of the sphincter of Oddi in man.

Authors:  J C Cuer; M Dapoigny; S Ajmi; J L Larpent; B Lunaud; C Ferrier; G Bommelaer
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Subarachnoid buprenorphine administered by implantable micropumps.

Authors:  N Francaviglia; C Silvestro; F Carta; V Davini; C Perria; I Scaricabarozzi; P V Cipolla
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

6.  Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study.

Authors:  Joseph Gimbel; Egilius L H Spierings; Nathaniel Katz; Qinfang Xiang; Evan Tzanis; Andrew Finn
Journal:  Pain       Date:  2016-11       Impact factor: 7.926
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.